Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer
Update: 2025-11-04
Description
Novo Nordisk ups the ante in bidding war for Metsera, offering up to $10 billion, surpassing Pfizer's latest bid. Metsera, with no marketed drugs, has attracted massive interest due to its promising obesity and diabetes treatments. Pfizer's CEO questions the feasibility of Novo's proposal, leaving uncertainty about the next move.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
